FOXP1 and non-small cell lung carcinoma: Employing CRISPR-CAS9 technology to knock out Foxp1 in NSCLC cells, the Western blot analysis demonstrated the downregulation of the CTLA4 level in Foxp1-deficient NSCLC cells.